Effects of nile tilapia (Oreochromis niloticus) viscera hydrolyzate on blood pressure, TNF-α and IL-6 expression in rats (Rattus norvegicus) induced by DOCA-Salt

Background: Hypertension is a disease that has the potential to become the most significant cause of death in the world in 2020. Hypertension caused by an imbalance of the renin angiotensinogen system. Viscera hydrolyzate extract has an anti-hypertension activity. The research aimed to determine tilapia viscera hydrolyzate extract’s ability to reduce blood pressure, suppressing the expression of TNF-α and IL-6. Viscera hydrolyzed with alcalase and extracted to obtain viscera bioactive crude extract (VisBC). Methods: Spontaneously hypertensive rats induced by DOCA-salt, gave VisBC therapy. 15 Wistar rats divided into 5 treatment groups, namely normal control (without induced DOCA-salt), positive control (SHR-Spontaneous Hypertensive Rat = induced by DOCA-salt), comparative control (SHR + Captopril 5 mg/kg), VisBC 1 (SHR + BC 150 mg/kg) and VisBC 2 (SHR + BC 300 mg/kg), where each treatment consisted of 3 replications. Each treatment measured for blood pressure, TNF-α and IL-6 expression. The data represented as mean ± SD and analyzed by ANOVA (p<0.05) in any difference, a subsequent Duncan test. Data analyzed by SPSS 20.0 for Windows 10. Result: The results showed the treatment of VisBC could reduce systole (19.64%) and diastole (29.15%) blood pressure. Also, VisBC inhibited the expression of TNF-α (8.08%) and IL-6 (8.39%). The VisBC of tilapia with a dose of 150 mg/kg could inhibit the expression of TNF-α and IL-6, thereby affected the decrease in blood pressure (systole and diastole) in rats induced by DOCA-salt. This research proved that fish waste could produce bioactive as anti-hypertension.